MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Abeona Therapeutics Inc

Cerrado

4.67 4.71

Resumen

Variación precio

24h

Actual

Mínimo

4.41

Máximo

4.9

Métricas clave

By Trading Economics

Empleados

136

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+298.93% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

4.4M

218M

Apertura anterior

-0.04

Cierre anterior

4.67

Abeona Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 abr 2024, 23:00 UTC

Principales Movimientos del Mercado

Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter

Comparación entre iguales

Cambio de precio

Abeona Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

298.93% repunte

Estimación a 12 meses

Media 18.67 USD  298.93%

Máximo 25 USD

Mínimo 15 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Abeona Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Finanzas

$

Acerca de Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.